![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » ARGOS BEGINS PHASE I/II TRIAL OF CANCER IMMUNOTHERAPY
ARGOS BEGINS PHASE I/II TRIAL OF CANCER IMMUNOTHERAPY
August 22, 2006
Argos Therapeutics announced that dosing has been initiated in a Phase I/II clinical trial to test the activity and safety of AGS-003, a personalized immunotherapy for advanced kidney cancer. AGS-003 is a second-generation dendritic cell-based therapy with optimized immune response characteristics that is designed to stimulate the patient's immune system to target and destroy the cancer cells.
Approximately 26 patients with newly diagnosed metastatic renal-cell carcinoma will be enrolled in the Phase I/II trial at multiple centers in the U.S. and Canada. The primary objective of the trial is to measure T-cell responses to treatment. Secondary trial objectives include safety assessments and confirming the feasibility of using a new manufacturing process, which may enhance production efficiency as well as the strength of the immune response induced by AGS-003. The trial will also measure clinical anti-tumor activity, progression-free survival and overall survival.
Argos's proprietary approach to personalized immunotherapy is based on optimizing a patient's own dendritic cells to trigger a tumor-specific immune response. To address the challenge of the unique genetic profile of each patient's cancer and the genetic mutations of that cancer, Argos loads the autologous dendritic cells with a patient's total tumor RNA.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct